PET evaluation of drugs in Alzheimer's and Parkinson's diseases

Drug Information Journal

Volumn 31, Issue 3, 1997, Pages 1035-1044

  Herholz, Karl ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Alzheimer's disease; Fluorodeoxyglucose; Fluorodopa; Parkinson's disease; PET

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; ACETYLCHOLINESTERASE; BETA GLUCURONIDASE; CARBON 11; CHOLINE ACETYLTRANSFERASE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUTAMINASE; HEXOKINASE; LEVODOPA; LIGAND; LISURIDE; OXYGEN 15; PENICILLAMINE; PIRACETAM; RACLOPRIDE; RECEPTOR; SCOPOLAMINE; TACRINE;

ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; GLUCOSE METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DENSITY;

EID: 0030840830     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159703100348     Document Type: Article

References (94)

1. Yarowsky P, Crane A, Sokoloff L. Metabolic activation of specific postsynaptic elements in superior cervical ganglion by antidromic stimulation of external carotid nerve. Brain Research. 1985;334:330-334.
2. Sokoloff L. Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. [Review]. J Cerebral Blood Flow Metabol. 1981;l:7-36.
3. 18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circula Res. 1979;44:127-137.
4. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochemis. 1977;28:897-916.
5. Kuhl DE, Metter EJ, Riege WH, Hawkins RA. The effect of normal aging on patterns of local cerebral glucose utilization. Ann Neurology. 1984;15 Suppl: S133-137.
6. Duara R, Margolin RA, Robertson-Tchabo EA, et al. Cerebral glucose utilization, as measured with positron emission tomography in 21 resting healthy men between the ages of 21 and 83 years. Brain. 1983;106:761-775.
7. Moeller JR, Ishikawa T, Dhawan V, et al. The metabolic topography of aging. J Cerebral Blood Flow Metabol. 1996;16:385-398.
8. Wang GJ, Volkow ND, Wolf AP, Brodie JD, Hitzemann RJ. Intersubject variability of brain glucose metabolic measurements in young normal males [see comments]. J Nuclear Med. 1994;35:1457-1466.
9. Bartlett EJ, Brodie JD, Wolf AP, Christman DR, Laska E, Meissner M. Reproducibility of cerebral glucose metabolic measurements in resting human subjects. J Cerebral Blood Flow Metabol. 1988;8: 502-512.
10. Mann JJ, Malone KM, Diehl DJ, Perel J, Nichols TE, Mintun MA. Positron emission tomographic imaging of serotonin activation effects on prefrontal cortex in healthy volunteers. J Cerebral Blood Flow Metabol. 1996; 16:418-426.
11. Rapoport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis - A critical review. Cerebrovascular Brain Metabol Rev. 1991;3:297-335.
12. Schapiro MB, Ball MJ, Grady CL, Haxby JV, Kaye JA, Rapoport SI. Dementia in Down's syndrome: cerebral glucose utilization, neuropsychological assessment, and neuropathology. Neurology. 1988;38: 938-942.
13. Polinsky RJ, Noble H, Di Chiro G, Nee LE, Feldman RG, Brown RT. Dominantly inherited Alzheimer's disease: cerebral glucose metabolism. J Neural, Neurosurg Psychiatry. 1987;50:752-757.
14. Guze BH, Huffman JM, Mazziotta JC, Baxter LR, Jr., Phelps ME. Positron emission tomography and familial Alzheimer's disease: a pilot study. J Am Geriatrics Soc. 1992;40:120-123.
15. Kennedy AM, Newman SK, Frackowiak RS, et al. Chromosome 14 linked familial Alzheimer's disease. A clinico-pathological study of a single pedigree. Brain. 1995;118:18S-205.
16. Kennedy AM, Rossor MN, Frackowiak RS. Positron emission tomography in familial Alzheimer disease. Alzheimer Dis Associat Disorders. 1995;9:17-20.
17. Herholz K. FDG PET and differential diagnosis of dementia. [Review]. Alzheimer Dis Associat Disorders. 1995;9:6-16.
18. Herholz K, Adams R, Kessler J, Szelies B, Grond M, Heiss WD. Criteria for the diagnosis of Alzheimer's disease with positron emission tomography. Dementia. 1990;1:156-164.
19. Herholz K, Perani D, Salmon E, et al. Comparability of FDG PET studies in probable Alzheimer's disease. J Nuclear Med. 1993;34:1460-1466.
20. Kamo H, McGeer PL, Harrop R, et al. Positron emission tomography and histopathology in Pick's disease. Neurology. 1987;37:439-445.
21. Szelies B, Karenberg A. Störungen des Glukosestoffwechsels bei Pick'scher Erkrankung. Fortschritte der Neurologie-Psychiatrie. 1986;54:393-397.
22. Salmon E, Franck G. Positron emission tomographic study in Alzheimer's disease and Pick's disease. Arch Gerontology Geriatrics. 1989;Suppl.1:241-247.
23. Friedland RP, Koss E, Lerner A, et al. Functional imaging, the frontal lobes, and dementia. Dementia. 1993;4:192-203.
24. Benson DF. Progressive frontal dysfunction. Dementia. 1993;4:149-153.
25. Brun A. Frontal lobe degeneration of non-Alzheimer type revisited. Dementia. 1993;4:126-131.
26. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology. 1983;33:961-965.
27. Haxby JV, Duara R, Grady CL, Cutler NR, Rapoport SI. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. Cerebral Blood Flow Metabol. 1985;5:193-200.
28. Grady CL, Haxby JV, Schlageter NL, Berg G, Rapoport SI. Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. Neurology. 1986;36:1390-1392.
29. Jagust WJ, Friedland RP, BudingerTF, Koss E, Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology. 1988;38: 909-912.
30. 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans. Canadian J Neurolog Sci. 1990;17:1-11.
31. Smith GS, de Leon MJ, George AE, et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurology. 1992;49: 1142-1150.
32. Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia. 1994;5: 36-41.
33. Heiss WD, Pawlik G, Holthoff V, Kessler J, Szelies B. PET correlates of normal and impaired memory functions. [Review]. Cerebrovascular Brain Metabol Rev. 1992;4:1-27.
34. Kuwert T, Homberg V, Steinmetz H, et al. Posthypoxic amnesia: regional cerebral glucose consumption measured by positron emission tomography. J Neurolog Sci. 1993;118:10-16.
35. 18F]FDG PET metabolic study. Brain. 1993;116: 903-919.
36. Fukuyama H, Harada K, Yamauchi H, et al. Coronal reconstruction images of glucose metabolism in Alzheimer's disease. J Neurolog Sci. 1991;106:128-134.
37. Slansky I, Herholz K, Pietrzyk U, et al. Cognitive impairment in Alzheimer's disease correlates with ventricular width and atrophy-corrected cortical glucose metabolism. Neuroradiology. 1995;37:270-277.
38. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. [Review]. Acta Neuropathologica. 1991;82.-239-259.
39. Haxby JV, Grady CL, Duara R, Schlageter N, Test T, Rapoport SI. Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia. Arch Neurology. 1986;43: 882-885.
40. Grady CL, Haxby JV, Horwitz B, et al. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clinical Experimen Neuropsychol. 1988;10: 576-596.
41. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E. New Eng J Med. 1996;334:752-758.
42. Grady CL, Haxby JV, Horwitz B, Berg, G, Rapoport SI. Neuropsychological and cerebral metabolic function in early vs late onset dementia of the Alzheimer type. Neuropsychologia. 1987;25:807-816.
43. Small GW, Kuhl DE, Riege WH, et al. Cerebral glucose metabolic patterns in Alzheimer's disease. Effect of gender and age at dementia onset. Arch Gen Psychiatry. 1989;46:527-532.
44. Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiology Aging. 1992; 13: 93-98.
45. Kiyosawa M, Baron JC, Hamel E, et al. Time course of effects of unilateral lesions of the nucleus basalis of Meynert on glucose utilization by the cerebral cortex. Positron tomography in baboons. Brain. 1989;112:435-455.
46. Demicheli E, Soncrant TT. Age-dependent cerebral metabolic effects of unilateral nucleus basalis magnocellularis ablations in rats. Neurobiology Aging. 1992;13:687-695.
47. Nishiyama K, Momose T, Sugishita M, Sakuta M. Positron emission tomography of reversible intellectual impairment induced by long-term anticholinergic therapy. J Neurolog Sci. 1995;132:89-92.
48. Cohen RM, Gross M, Semple WE, Nordahl TE, Sunderland T. The metabolic brain pattern of young subjects given scopolamine. Experimen Brain Res. 1994;100:133-143.
49. Blin J, Piercey MF, Giuffra ME, Mouradian MM, Chase TN. Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography. J Neurolog Sci. 1994;123: 44-51.
50. Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport. 1994;5:747-749.
51. Blin J, Mazetti P, Mazoyer B, et al. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy. Brain. 1995;118:1485-1495.
52. DeCarli C, Atack JR, Ball MJ, et al. Post-mortem neurofibrillary tangle densities but not senile plaque densities are related regional metabolic rates for glucose during life in Alzheimer's disease patients. Neurodegeneration. 1992;1:113-121.
53. McGeer PL, Kamo H, Harrop R, et al. Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease. Neurology. 1986;36: 1569-1574.
54. Mielke R, Schroder R, Fink GR, Kessler J, Herholz K, Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathologica. 1996;91:174-179.
55. McGeer EG, McGeer PL, Harrop R, Akiyama H, Kamo H. Correlations of regional postmortem enzyme activities with premortem local glucose metabolic rates in Alzheimer's disease. J Neuroscience Res. 1990;27:612-619.
56. Kessler J, Herholz K, Grond M, Heiss WD. Impaired metabolic activation in Alzheimer's disease: a PET study during continuous visual recognition. Neuropsychologia. 1991;29:229-243.
57. Duara R, Barker WW, Chang J, Yoshii F, Loewenstein DA, Pascal S. Viability of neocortical function shown in behavioral activation state PET studies in Alzheimer disease. J Cerebral Blood Flow Metabol. 1992;12:927-934.
58. Buchsbaum MS, Kesslak JP, Lynch G, et al. Temporal and hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and controls. Preliminary studies. Arch Gen Psychiatry. 1991;48:840-847.
59. 11C-2-deoxy-D-glucose and PET. J Cerebral Blood Flow Metabol. 1987;7:248-251.
60. Grady CL, Haxby JV, Horwitz B, et al. Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia. Neurobiology Aging. 1993;14:35-44.
61. Heiss WD, Hebold I, Klinkhammer P, et al. Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. J Cerebral Blood Flow Metabol. 1988; 8:613-617.
62. Szelies B, Herholz K, Pawlik G, Beil C, Wienhard K, Heiss WD. [Cerebral glucose metabolism in presenile dementia of the Alzheimer type - follow-up of therapy with muscarinergic choline agonists]. [German]. Fortschritte der Neurologie-Psychiatrie. 1986;54:364-373.
63. Nordberg A, Lilja A, Lundqvist H, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiology Aging. 1992;13:747-758.
64. Tune L, Brandt J, Frost JJ, et al. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatrica Scandinavica, Supplementum. 1991;366:61-65.
65. Heiss WD, Kessler J, Mielke R, Szelies B, Herholz K. Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG and PET investigation. Dementia. 1994;5:88-98.
66. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 1983; 305:137-138.
67. 18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurology. 1986;20:258-262.
68. l8F]fluoro-L-dopa for the in vivo study of intracerebral dopamine. Int J Radiation Applica Instrumenta - Part A, App Radiation Isotopes. 1986;37:669-675.
69. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain. 1990; 113:1539-1552.
70. Cordes M, Snow BJ, Cooper S, et al. Age-dependent decline of nigrostriatal dopaminergic function: a positron emission tomographic study of grandparents and their grandchildren. Ann Neurology. 1994; 36:667-670.
71. 18F-dopa uptake: absence of an aging effect [see comments]. J Cerebral Blood Flow Metabol. 1993;13: 881-888.
72. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurology. 1990;28:799-804.
73. Vingerhoets FJ, Snow BJ, Schulzer M, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nuclear Med. 1994:35:18-24.
74. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neural, Neurosurg Psychiatry. 1986;49:853-860.
75. Leenders KL, Salmon EP, Tyrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurology. 1990;47:1290-1298.
76. Sawle GV, Playford ED, Bum DJ, Cunningham VJ, Brooks DJ. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch Neurology. 1994;51:237-243.
77. Kuwabara H, Cumming P, Yasuhara Y, et al. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. J Nuclear Med. 1995; 36:1226-1231.
78. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurology. 1993;34:324-330.
79. Antonini A, Vontobel P, Psylla M, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurology. 1995;52:1183-1190.
80. 18F-dopa and positron emission tomography. Neurology. 1992:42:1894-1900.
81. 18F]dopa positron emission tomography studies in an Irish kindred. Ann Neurology. 1992:32:609-617.
82. 18F-dopa PET study. Neurology. 1993;43:552-556.
83. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic Parkinsonism. Ann Neurology. 1994;36: 759-764.
84. Barou JC, Cou D, Fardo L, Martinet JL, Matoyer B (eds). Brain dopaminergic systems: imaging with positron tomography. Dordrecht: Kluwer Academic Publishers; 1991.
85. 11C-raclopride and positron emission tomography. Ann Neurology. 1992;31: 184-192.
86. 2 receptor status. Brain. 1993;116:853-867.
87. 18F]fluorodopa positron emission tomographic studies. Move Disorders. 1990;5:203-213.
88. Perani D, Bressi S, Testa D, et al. Clinical/metabolic correlations in multiple system atrophy. A fludeoxyglucose F 18 positron emission tomographic study. Arch Neurology. 1995;52:179-185.
89. 18F]fluorodeoxyglucose method. Ann Neurology. 1984;15:419-424.
90. Peppard RF, Martin WR, Carr GD, et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurology. 1992;49:1262-1268.
91. 2-receptors. Neurology. 1994;44:1325-1329.
92. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 1990;247: 574-577.
93. 18F]fluorodopa uptake in five grafted Parkinsonian patients. Ann Neurology. 1995;38:580-588.
94. De Voider A, Sindic CJM, Goffmet AM. Effect of D-penicillamine treatment on brain metabolism in Wilson's disease: a case study. J Neural, Neurosurg Psychiatry. 1988;51:947-949.